- Abstract
- 10.1136/jnis-2024-snis.415
LB-016 Coiling of aneurysms smaller than 5 millimeters with HyperSoft® and HydroGel coils (COAST)
- Jul 01, 2024
- Journal of NeuroInterventional Surgery
- J Lena + 8 more +8
Introduction/PurposeLimited data exist regarding ≤4.9mm intracranial aneurysms’ natural history and there is even less prospective core lab adjudicated data on such aneurysms’ treatment safety and efficacy. ISUIA prospective data reported a 0-3.4% 5-year rupture risk for aneurysms <7.0mm depending on location and rupture history. The Sapporo SAH Study data stated that while small aneurysms’ rupture risk is low, aneurysm size ratio strongly predicts rupture in small aneurysms. Limited large multicenter adjudicated data regarding treatment efficacy and risk limits the risk-benefit assessment of treatment. COAST is a post-market single-arm core lab adjudicated multicenter study evaluating the safety and efficacy of coiling aneurysms ≤4.9mm in maximal diameter.Materials & MethodsEligible patients aged 18-80 presenting with a ≤4.9mm ruptured or unruptured saccular intracranial aneurysm suitable for endovascular coil occlusion were prospectively enrolled. Inclusion criteria required unruptured aneurysm patients to be mRS 0-2, and ruptured aneurysm patients to be Hunt & Hess ≤3. Framing was allowed with any bare metal coil or with HydroSoft 3D or HydroFrame coils, but the remainder of aneurysm coiling was required to be with HyperSoft, HydroSoft coils, HydroFrame or HydroFill coils. Angiographic and clinical outcome data was collected immediately post-procedure and at 6- and/or 12-month follow ups. The primary safety outcome was defined as freedom from imaging-confirmed new post-procedural hemorrhage or ischemic stroke associated with a ≥4-point NIHSS worsening within 48 hours or any new aneurysmal SAH secondary to the treated aneurysm, and the primary efficacy outcome was defined as adequate occlusion (Raymond Roy I/II) on >150 days post-embolization angiography, not requiring retreatment. Secondary outcomes included neurological morbidity or mortality, rebleeding, recurrence, and retreatment. Clinical outcomes were adjudicated by an independent safety monitor not otherwise involved in the trial, and radiographic outcomes were adjudicated by an independent core lab.ResultsOver 5.3 years, 15 centers prospectively enrolled 300 patients. Mean enrollment age was 55.6 years (76% female; 36.3% (n=109) presenting with SAH). Core lab adjudicated assessment demonstrates an initial adequate occlusion rate of 68.7% (ruptured: 76.2%; unruptured: 64.4%) and a 6-12-month adequate occlusion rate of 89.7% (ruptured: 81.0%; unruptured: 94.4%). At 6-12-month follow-up 1.2% of unruptured patients and 3.2% of ruptured patients exhibited an mRS score of 3-5. Mortality was 1.2% for unruptured and 7.4% for ruptured patients. Absence of the primary safety outcome was met by 99.3% of participants. Adequate occlusion without retreatment was 84.0%. 5.4% of patients experienced neurological morbidity or mortality. Rebleeding, recurrence, and retreatment rates were 0.7% (1.8% amongst ruptured patients only), 4.7%, and 6.3%, respectively.ConclusionThese data suggests that endovascular coiling of small aneurysms does not pose a greater patient risk than coiling of large aneurysms. Furthermore, endovascular occlusion demonstrates robust adequate occlusion rates. These data contribute high quality, prospective, independent safety monitor and core-lab adjudicated data to the risk-benefit assessment of small aneurysm treatment.DisclosuresJ. Lena: None. C. van der Wegen: None. D. Fiorella: 1; C; Microvention. 2; C; Microvention. J. Fifi: 2; C; Microvention. K. Woodward: None. B. Baxter: None. R. Hanel: 1; C; Microvention. 2; C; Microvention. A. Turk: None. J. Mocco: 1; C; Microvention.
Read more